3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
219
Neoplasms
15
Neoplasm Metastasis
12
Carcinoma, Intraductal, Noninfiltrating
10
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
7
Advanced Breast Cancer
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasm Female
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Seizures
1
Sarcoma
1
Recurrence
1
Quality of Life
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
Anastrozole
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled